Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing
Open Access
- 22 October 2013
- journal article
- review article
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 6 (1) , 79
Abstract
Ruxolitinib, an oral JAK1 and JAK2 inhibitor, is approved in the US for patients with intermediate or high-risk myelofibrosis (MF), a chronic neoplasm associated with aberrant myeloproliferation, progressive bone marrow fibrosis, splenomegaly, and burdensome symptoms. Phase III clinical studies have shown that ruxolitinib reduces splenomegaly and alleviates MF-related symptoms, with concomitant improvements in quality of life measures, for the overwhelming majority of treated patients. In addition, ruxolitinib provided an overall survival advantage as compared with either placebo or what was previously considered best available therapy in the two phase III studies. The most common adverse events with ruxolitinib treatment include dose-dependent anemia and thrombocytopenia, which are expected based on its mechanism of action. Experience from the phase III studies shows that these hematologic events can be managed effectively with dose modifications, temporary treatment interruptions, as well as red blood cell transfusions in the case of anemia and, importantly, are rarely cause for permanent treatment discontinuation. This review summarizes data supporting appropriate individualized patient management through careful monitoring of blood counts and dose titration as needed in order to maximize treatment benefit.Keywords
This publication has 27 references indexed in Scilit:
- Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomesOncoTargets and Therapy, 2013
- Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancerOncoTargets and Therapy, 2013
- The evolving treatment paradigm in myelofibrosisLeukemia & Lymphoma, 2012
- Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitorsJournal of Hematology & Oncology, 2012
- Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post-ASH symposiumAmerican Journal of Hematology, 2012
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasmsBlood, 2010
- Primary Myelofibrosis: Update on Definition, Pathogenesis, and TreatmentAnnual Review of Medicine, 2009
- Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromesAnnals of Hematology, 2008
- Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasiaExperimental Hematology, 2006
- Serum interleukin (IL)‐1, IL‐2, sIL‐2Ra, IL‐6 and thrombopoietin levels in patients with chronic myeloproliferative diseasesBritish Journal of Haematology, 2005